ORIC Pharmaceuticals

Contributing Author

Recent Articles by ORIC Pharmaceuticals

Mar-06	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) ORIC GlobeNewswire
Feb-23	ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates ORIC +14.60% ORIC +5.40% GlobeNewswire
Feb-06	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) ORIC GlobeNewswire
Feb-05	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences ORIC -6.13% GlobeNewswire
Jan-12	ORIC Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones ORIC GlobeNewswire
Jan-06	ORIC Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference ORIC +6.63% ORIC GlobeNewswire
Dec-05	ORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025 ORIC GlobeNewswire
Dec-05	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) ORIC GlobeNewswire
Dec-05	ORIC Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025 ORIC GlobeNewswire
Dec-04	ORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025 ORIC GlobeNewswire
Dec-03	ORIC Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025 ORIC GlobeNewswire
Dec-01	ORIC Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025 ORIC -6.14% GlobeNewswire
Nov-24	ORIC Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference ORIC GlobeNewswire
Nov-13	ORIC Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates ORIC GlobeNewswire
Nov-13	ORIC Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety ORIC GlobeNewswire
Nov-07	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) ORIC GlobeNewswire
Nov-06	ORIC Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor ORIC GlobeNewswire
Nov-04	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences ORIC GlobeNewswire
Oct-27	ORIC Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors ORIC GlobeNewswire
Sep-05	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) ORIC GlobeNewswire
Aug-27	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences ORIC GlobeNewswire
Aug-18	ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer ORIC GlobeNewswire
Aug-12	ORIC Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates ORIC GlobeNewswire
Aug-01	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) ORIC GlobeNewswire
Jul-03	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) ORIC GlobeNewswire
Jun-06	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) ORIC +5.79% ORIC GlobeNewswire
May-28	ORIC Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC ORIC +33.50% ORIC GlobeNewswire
May-28	ORIC Pharmaceuticals Announces $125 Million Private Placement Financing ORIC +33.50% ORIC GlobeNewswire
May-27	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences ORIC -8.98% GlobeNewswire
May-27	ORIC Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC ORIC -8.98% GlobeNewswire
May-05	ORIC Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates ORIC -11.58% ORIC GlobeNewswire
May-02	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) ORIC GlobeNewswire

ORIC Pharmaceuticals

Recent Articles by ORIC Pharmaceuticals

Upgrade your FINVIZ experience